MX2016015389A - Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. - Google Patents

Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.

Info

Publication number
MX2016015389A
MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A
Authority
MX
Mexico
Prior art keywords
human
cynomolgus
antibody
epsilon
cells
Prior art date
Application number
MX2016015389A
Other languages
English (en)
Inventor
Lifke Valeria
Offner Sonja
Moessner Ekkehard
Jaeger Christiane
Ritter Mirko
Platzer Josef
Tiefenthaler Georg
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016015389A publication Critical patent/MX2016015389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Un aspecto como se reporta en la presente es el uso de un método que comprende la etapa de inmunizar a un animal experimental tres veces con PBLs primarios de mono cinomolgo, por lo cual los PBLs enriquecen opcionalmente las células T sin utilizar PBLs humanos primarios como inmuógeno y sin utilizar un agente desnaturalizante para producir un anticuerpo de reacción cruzada humano-cinomolgo que se enlaza específicamente al CD3 épsilon humano de la SEQ ID NO: 02 y se enlaza específicamente a un polipéptido de la SEQ ID NO: 01, en donde el anticuerpo de reacción cruzada humano-cinomolgo se enlaza específicamente a las células T humanas y de mono cinomolgo, activa las células T humanas y no se enlaza al mismo epítopo que el anticuerpo OKT3, el anticuerpo UCHT1 y/o el anticuerpo SP34.
MX2016015389A 2014-05-28 2015-05-22 Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. MX2016015389A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14170140 2014-05-28
EP14180572 2014-08-11
PCT/EP2015/061457 WO2015181098A1 (en) 2014-05-28 2015-05-22 Antibodies binding to human and cynomolgus cd3 epsilon

Publications (1)

Publication Number Publication Date
MX2016015389A true MX2016015389A (es) 2017-04-13

Family

ID=53268799

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015389A MX2016015389A (es) 2014-05-28 2015-05-22 Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.

Country Status (13)

Country Link
US (3) US20170233475A1 (es)
EP (2) EP3763739A1 (es)
JP (1) JP6738285B2 (es)
KR (1) KR20170003591A (es)
CN (1) CN106459201A (es)
AU (1) AU2015266077A1 (es)
BR (1) BR112016022819A2 (es)
CA (1) CA2942453A1 (es)
IL (1) IL247740A0 (es)
MX (1) MX2016015389A (es)
RU (1) RU2016151235A (es)
SG (1) SG11201609950YA (es)
WO (1) WO2015181098A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7325186B2 (ja) 2015-12-09 2023-08-14 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗薬物抗体の形成を減少させるためのｉｉ型抗ｃｄ２０抗体
WO2017150762A1 (ko) * 2016-02-29 2017-09-08 (주)메디톡스 항-CD3γε 항체 및 이의 용도
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
TW201902512A (zh) 2016-06-02 2019-01-16 瑞士商赫孚孟拉羅股份公司 治療方法
JP7202185B2 (ja) * 2016-12-22 2023-01-11 第一三共株式会社 抗ｃｄ３抗体及び該抗体を含む分子
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
JP7247110B2 (ja) 2017-06-05 2023-03-28 ヌマブ セラピューティクス アクチェンゲゼルシャフト 新規抗ｃｄ３抗体
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
CN110831965B (zh) 2017-06-21 2023-03-07 吉利德科学公司 靶向hiv gp120和cd3的多特异性抗体
EP3684806A4 (en) 2017-09-21 2021-09-22 Wuxi Biologics (Cayman) Inc. NEW ANTI-CD3EPSILON ANTIBODIES
EP3717632B1 (en) * 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method
WO2019175658A1 (en) * 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof
JOP20200302A1 (ar) * 2018-05-24 2020-11-23 Janssen Biotech Inc الأجسام المضادة لـ cd3 واستخداماتها
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
TW202210510A (zh) * 2020-05-27 2022-03-16 美商健生生物科技公司 包含ｃｄ３抗原結合域之蛋白質及其用途
WO2022063819A1 (en) * 2020-09-24 2022-03-31 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
AU2021443863A1 (en) 2021-04-30 2023-10-26 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
EP4330282A1 (en) 2021-04-30 2024-03-06 F. Hoffmann-La Roche AG Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN113755435B (zh) * 2021-10-15 2023-10-13 苏州药明康德新药开发有限公司 一种食蟹猴pbmc分离方法
WO2023183766A1 (en) * 2022-03-20 2023-09-28 Abcellera Biologics Inc. Anti-cd3 antibodies and t-cell engagers and methods of use
WO2023180346A1 (en) * 2022-03-22 2023-09-28 Morphosys Ag Deimmunized antibodies specific for cd3
TW202346365A (zh) 2022-03-23 2023-12-01 瑞士商赫孚孟拉羅股份公司 抗ｃｄ２０／抗ｃｄ３雙特異性抗體及化學療法之組合治療
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD272473B3 (de) * 1988-06-13 1993-01-21 Univ Leipzig Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten
JPH0630786A (ja) * 1992-07-14 1994-02-08 Kyowa Hakko Kogyo Co Ltd バイスペシフィック抗体
US7728114B2 (en) * 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
AU2006301492B2 (en) * 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
PT2155788E (pt) * 2007-04-03 2012-09-25 Micromet Ag Aglutinantes duplamente específicos, específicos interespécies
CN103842383B (zh) * 2011-05-16 2017-11-03 健能隆医药技术（上海）有限公司 多特异性fab融合蛋白及其使用方法
SG195072A1 (en) * 2011-05-21 2013-12-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
WO2015172800A1 (en) * 2014-05-12 2015-11-19 Numab Ag Novel multispecific molecules and novel treatment methods based on such multispecific molecules

Also Published As

Publication number Publication date
WO2015181098A1 (en) 2015-12-03
CN106459201A (zh) 2017-02-22
BR112016022819A2 (pt) 2018-01-16
US20200299385A1 (en) 2020-09-24
RU2016151235A3 (es) 2019-01-18
EP3149041A1 (en) 2017-04-05
AU2015266077A1 (en) 2016-09-29
CA2942453A1 (en) 2015-12-03
IL247740A0 (en) 2016-11-30
JP6738285B2 (ja) 2020-08-12
JP2017516786A (ja) 2017-06-22
US20200325224A1 (en) 2020-10-15
SG11201609950YA (en) 2016-12-29
KR20170003591A (ko) 2017-01-09
RU2016151235A (ru) 2018-06-28
EP3763739A1 (en) 2021-01-13
US20170233475A1 (en) 2017-08-17

Similar Documents

Publication Publication Date Title
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
MX2017012802A (es) Anticuerpos antisortilina y métodos para su uso.
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
MX2020003046A (es) Anticuerpos anti-hla-a2 y metodos para utilizar los mismos.
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
NZ714516A (en) Human antibodies to clostridium difficile toxins
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
MX2022007774A (es) Anticuerpos de union a abril modificados.
AU2014236098A8 (en) Treatment of cancer using humanized anti-CD19 chimeric antigen receptor
JP2017516786A5 (es)
MX341958B (es) Anticuerpos contra el il33r humano y usos de los mismos.
AR091605A1 (es) Proteinas de union anti-mesotelina
PH12021550041A1 (en) Anti-sortilin antibodies and methods of use thereof
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
SG10201803473WA (en) Methods for enhancing immunosuppressive therapy by multiple administration of alpha beta tcr-binding polypeptide
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2022007231A (es) Anticuerpos anti-mertk y metodos de uso de los mismos.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
NZ595863A (en) Antibodies to egfl7 and methods for their use
MX2022001260A (es) Anticuerpos anti-ms4a4a y metodos de uso de los mismos.
MX2021000933A (es) Anticuerpos anti-siglec-5 y métodos para su uso.
AU2018338423A1 (en) Novel anti-HLA-A2 antibodies and uses thereof